Bioventus, Inc. (BVS)
| Market Cap | 507.50M |
| Revenue (ttm) | 430.90M |
| Net Income (ttm) | 19.38M |
| Shares Out | 61.66M |
| EPS (ttm) | -1.05 |
| PE Ratio | n/a |
| Forward PE | 17.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,959 |
| Open | 8.36 |
| Previous Close | 8.47 |
| Day's Range | 8.13 - 8.73 |
| 52-Week Range | 6.30 - 17.53 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 17.85 (+116.9%) |
| Earnings Date | Aug 11, 2022 |
About BVS
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for... [Read more...]
Financial Performance
In 2021, Bioventus's revenue was $430.90 million, an increase of 34.17% compared to the previous year's $321.16 million. Earnings were $19.38 million, an increase of 18.06%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for BVS stock is "Buy." The 12-month stock price forecast is 17.85, which is an increase of 116.89% from the latest price.
News
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the t...
Bioventus Receives FDA 510(k) Clearance for SonaStar Elite
Innovative New Handpiece Addition to the Nexus Ultrasonic Generator
Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022
DURHAM, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financ...
Bioventus Completes CartiHeal Acquisition
DURHAM, N.C., July 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its ...
Bioventus Amends CartiHeal Acquisition Structure
DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into a...
Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three ...
Bioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial Guidance
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that its subsidiary, Bioven...
Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis
DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Ci...
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA
DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary financial res...
Bioventus Announces $415 Million Offering of Senior Notes
DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that, subject to market c...
Bioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
DURHAM, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report finan...
Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives
DURHAM, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that TheraSkin coverage n...
Bioventus Announces Inducement Equity to SVP Chief Financial Officer Mark Singleton
DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on April 4, ...
Why Bioventus Stock Is Sinking Today
Investors aren't happy about the company's acquisition plans.
Bioventus Exercises Call Option to Acquire CartiHeal
DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has exercised its...
Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference
DURHAM, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will participat...
Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance
DURHAM, N.C., March 10, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the ...
Bioventus Receives 510(k) Clearance for StimRouter Pain Management Device
Industry Leading Peripheral Nerve Stimulator Upgraded to Improve Patient User Experience with Control of their Unique Chronic Pain Condition, Longer Battery Life Industry Leading Peripheral Nerve Stimul...
Bioventus Appoints Mark Singleton as Chief Financial Officer
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has appointed Mark...
Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022
DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financ...
Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue
DURHAM, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary revenue result...
Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at ...
Bioventus Appoints Michelle McMurry-Heath to Board of Directors
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Michelle ...
Bioventus Receives US FDA Clearance for BoneScalpel® Access™
DURHAM, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administrat...
Bioventus to Expand Operations and Manufacturing in Memphis
MEMPHIS, Tenn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has signed a lease agreement to double i...